The U.S. Food and Drug Administration (FDA) has granted approval for application ANDA087463. The approved product is marketed under the brand name Oxycet, a prescription oral tablet that combines oxycodone hydrochloride (5 mg) with acetaminophen (325 mg).
The product is classified as a human prescription drug and is manufactured by SpecGx LLC. It is listed under the generic name Oxycodone Hydrochloride and Acetaminophen and is available in multiple NDC package codes (e.g., 0406-0512-01, 0406-0522-05, etc.).
Submission history shows a series of manufacturing (CMC) and labeling supplements dating back to 1988, with the most recent labeling supplement (submission number 56) approved on March 4, 2024. All submissions to date have received an "AP" (Approved) status.
The tablet is intended for oral administration and is designated as a prescription‑only medication.
Actualizaciones regulatorias28 sept 2026•1 min de lectura
FDA Approves ANDA087463 for Oxycet (Oxycodone/Acetaminophen) Tablet
The FDA has approved ANDA087463 for the oral tablet Oxycet, containing 5 mg oxycodone hydrochloride and 325 mg acetaminophen, manufactured by SpecGx LLC.
Recopilado por el equipo de PharmaCountry · Fuente: FDA.gov
Calificaciones
(0)
(0)
(0)
(0)
(0)
Más artículos
Ver todos los artículosInvestigación e Informes
Global Finished Dosage Manufacturing Landscape 2026
5 oct 2026
Actualizaciones regulatoriasKorea Korus hit with 1‑month manufacturing suspension over missing post‑marketing safety test
28 sept 2026
AnálisisPharma distributors set delivery cut‑offs ahead of Chuseok holiday (Sep 21‑23)
28 sept 2026
Deja tu valoración